Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar wontfindaname (< 20) Submitted: 3/18/2008 5:49:41 PM : Outperform Start Price: $2.46 DVAX Score: +50.84

Expect the huge gap to get filled over the next few days and a slow rise back to 6 over the next couple of months.

Featured Broker Partners


Advertisement